Market Size and Growth Outlook
The Global Human Growth Hormone (HGH) Drugs Market is projected to grow from USD 5.85 Billion in 2024 to USD 11.50 Billion by 2035. The market is estimated at USD 6.20 Billion in 2025 and is expected to expand at a CAGR of 6.4% during the forecast period from 2026 to 2035.
Key Report Highlights
Human growth hormone drugs represent a specialized segment of the biopharmaceutical industry focused on recombinant human growth hormone (rhGH) formulations and advanced long-acting growth hormone analogs used to treat growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, chronic kidney disease-related growth failure, idiopathic short stature, and small for gestational age (SGA) conditions. Since the introduction of recombinant human growth hormone therapy, treatment outcomes for pediatric and adult patients have significantly improved through safer and more effective therapeutic options. The global treatment population currently includes approximately 285,000 pediatric patients and 175,000 adult patients receiving growth hormone therapy, while an estimated 1.8–2.2 million patients remain undiagnosed or untreated globally, presenting significant market expansion opportunities.
The development is fueled by the introduction of long-acting growth hormone formulations, transforming treatment from daily injections to a once weekly administration pattern. Novel products, such as the once weekly growth hormone treatments have been shown to improve patients' adherence and persistence. Increased clinical awareness, diagnostic improvements, enhancement of endocrinology specialist networks and integration of connected injection devices to digital health platforms is adding to the market growth. The increasing availability of the market, new opportunities are arising due to developments in precision medicine, biomarker-guided therapeutic adjustment, smart injection technology and enhanced healthcare access in emerging markets such as China, India, Brazil, and South East Asia.
By product type, Daily Growth Hormone Injections dominated the market with USD 4,588 Million in revenue during 2025, accounting for 74.0% of total market value. The segment continues to benefit from established clinical evidence, widespread physician familiarity, and broad reimbursement coverage. Long-Acting Growth Hormone Formulations accounted for 26.0% of the market and are expected to register the fastest growth owing to improved treatment adherence and enhanced patient convenience. By application, Pediatric Growth Hormone Deficiency was the largest sector with a 52.0% of the market share, attributed to a higher rate of diagnosis and positive long-term results of treatment. Adult Growth Hormone Deficiency accounted for 22.0% of the market share whereas other indicated conditions together represented 26.0% of the market share value.
North America dominated the global human growth hormone drugs market with a valuation of USD 2,666 Million in 2025, accounting for 43.0% of global revenue. The region benefits from advanced endocrinology care infrastructure, strong reimbursement frameworks, high diagnosis rates and early adoption of innovative long-acting therapies. Europe represented 31.0% of global market value, supported by universal healthcare systems and strong biosimilar adoption across major countries. With a growth rate of 6.8%, the Asia-Pacific region is anticipated to register the highest growth rate during the forecast period due to increased health infrastructure, expanding middle-class segment, surging healthcare expenses, increasing knowledge regarding growth disorders, and escalating demand from countries like China, Japan, South Korea and India.
Human Growth Hormone Drugs Market Trends
- Growing adoption of long-acting growth hormone formulations that reduce injection frequency and improve patient adherence.
- Increasing use of connected injection devices and mobile health applications for treatment monitoring and compliance management.
- Rising diagnosis rates of pediatric and adult growth hormone deficiency through improved clinical awareness and standardized guidelines.
- Expansion of biosimilar growth hormone products improving affordability and treatment accessibility across multiple regions.
- Ongoing research into oral, intranasal and transdermal growth hormone delivery technologies to reduce dependence on injectable therapies.
List of Key Players in the Human Growth Hormone Drugs Market:
- Novo Nordisk
- Pfizer Inc.
- Ascendis Pharma
- Eli Lilly and Company
- Merck KGaA
- Sandoz
- Changchun GeneScience Pharmaceutical Co.
- Ferring Pharmaceuticals
Human Growth Hormone Drugs Market Segmentation
The Human Growth Hormone Drugs Market can be segmented on the basis of Product Type, Application, and Distribution.
Human Growth Hormone Drugs Market Product Type Outlook, Revenue (USD Billion) (2025-2035)
• Daily Injections
• Long-Acting Formulations
Human Growth Hormone Drugs Market Application Outlook, Revenue (USD Billion) (2025-2035)
• Pediatric GHD
• Adult GHD
• Other Indications
Human Growth Hormone Drugs Market Distribution Outlook, Revenue (USD Billion) (2025-2035)
• Hospital Pharmacies
• Retail / Specialty
• Online
• Others
Human Growth Hormone Drugs Market Regional Outlook, Revenue (USD Billion) (2025-2035)
- North America
- Canada
- Mexico
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Europe
- Germany
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Latin America
- Argentina
- Brazil
- Chile
- Middle East and Africa
- GCC
- Turkey
- South Africa